Anti-BCMA CAR-T Cell Therapy for the Relapsed or Refractory Multiple Myeloma: a Multi-center, Uncontrolled Trial.
Latest Information Update: 07 Nov 2023
Price :
$35 *
At a glance
- Drugs Anti BCMA CAR T cell therapy-Carbiogene Therapeutics (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions
- 26 Nov 2020 New trial record